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Statement of translational relevance: Hormone receptor-positive (HR+) breast cancer is 
clinically and biologically heterogeneous and subgroups with different prognostic and 
treatment sensitivities need to be identified. Here, we present the development and clinical 
validation across multiple studies of a gene expression-based predictor, based on the well- 
known PAM50 assay, is associated with chemotherapy and endocrine therapy response in 
early breast cancer beyond PAM50 Risk of Relapse (ROR) and intrinsic subtypes. The 
potential clinical utility of this PAM50-based chemo-endocrine score (CES) predictor 
might be in the PAM50 ROR-intermediate, where the proportion of each CES group 
(endocrine-sensitive, intermediate and chemo-sensitive) is more than 25%. This is 
important as we await the results of large adjuvant clinical trials such as TailorX or 
RxPonder that have randomized patients with intermediate risk to adjuvant chemotherapy 
or not. 
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Abstract 
Purpose: Hormone receptor-positive (HR+) breast cancer is clinically and biologically 
heterogeneous and subgroups with different prognostic and treatment sensitivities need to 
be identified. 
 
Experimental design: Research-based PAM50 subtyping and expression of additional 
genes was performed on 63 patients with HR+/HER2- disease randomized to neoadjuvant 
multi-agent chemotherapy versus endocrine therapy in a phase II trial. The biology 
associated with treatment response was used to derive a PAM50-based Chemo-Endocrine 
Score (CES). CES´s predictive ability was evaluated in 4 independent neoadjuvant datasets 
(n=675) and 4 adjuvant datasets (n=1,505). The association of CES, intrinsic biology and 
PAM50 risk of relapse (ROR) was explored across 6,007 tumors. 
 
Results: Most genes associated with endocrine sensitivity were also found associated with 
chemotherapy resistance. In the chemotherapy test/validation datasets, CES was 
independently associated with pathological complete response (pCR), even after adjusting 
for intrinsic subtype. pCR rates of the CES endocrine sensitive (CES-E), uncertain (CES- 
U) and chemotherapy sensitive (CES-C) groups in both datasets combined were 25%, 11% 
and 2%, respectively. In the endocrine test/validation datasets, CES was independently 
associated with response. Compared to ROR, >90% of ROR-low and ROR-high tumors 
were identified as CES-E and CES-C, respectively; however, each CES-group represented 
>25% of ROR-intermediate disease. In terms of survival outcome, CES-C was associated 
with poor relapse-free survival in patients with ROR-intermediate disease treated with 
either adjuvant endocrine therapy-only or no adjuvant systemic therapy, but not in patients 
treated with (neo)adjuvant chemotherapy. 
 
Conclusions: CES is a genomic signature capable of estimating chemo-endocrine 
sensitivity in HR+ breast cancer beyond intrinsic subtype and risk of relapse. 
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Introduction 
Approximately 70% of invasive breast cancers at diagnosis are hormone receptor- 
positive and HER2-negative (HR+/HER2-)
1,2
. However, HR+/HER2- disease is clinically 
and biologically heterogeneous and further subclassifications are needed to better tailor 
current and future treatments
3-5
. 
Over the last decade, molecular characterization studies have identified and 
extensively investigated the two main molecular subtypes within HR+/HER2- disease (i.e. 
Luminal A and B)
1,2,6
. Luminal A tumors have an improved prognosis at 5- and 10-year 
follow-up compared with Luminal B tumors irrespective of classical clinical-pathological 
variables (e.g. tumor size and nodal status) and (neo)adjuvant treatment (i.e. endocrine and 
chemotherapy)
1,2,7,8
. In terms of treatment sensitivity, Luminal A tumors achieve significant 
lower rates of pathological complete response (pCR) than Luminal B tumors following 
neoadjuvant multi-agent chemotherapy
9-12
. However, less clear is the difference in 
endocrine sensitivity between the two luminal subtypes
13,14
. 
Today, adjuvant endocrine therapy for 5-10 years is recommended for all patients 
with HR+/HER2- early breast cancer, whereas chemotherapy is recommended for patients 
with intermediate and high risk tumors
15
. However, the relationship between therapy and 
risk warrants further study considering that risk is associated with both factors related to 
tumor biology and clinical-pathological features such as tumor size and nodal status, 
whereas therapy responsiveness is generally considered to be independent of clinical- 
pathological factors. 
 
Methods and Materials 
GEICAM/2006-03 clinical trial 
Pre-treatment core biopsy samples from patients recruited in the luminal cohort of 
the GEICAM/2006-03 phase II neoadjuvant clinical trial were evaluated
16
. In this study, 95 
patients with estrogen receptor (ER)-positive (Allred 3–8), progesterone receptor (PR)- 
positive (Allred 3–8), HER2- (according to the ASCO/CAP guidelines17), and cytokeratin 
8/18-positive breast cancer were randomly assigned to receive 24 weeks of neoadjuvant 
chemotherapy or endocrine therapy. Chemotherapy consisted of epirubicin combined with 
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cyclophosphamide for 4 cycles followed by docetaxel for 4 cycles. Endocrine therapy 
consisted of oral exemestane. Premenopausal patients received goserelin for 6 doses. 
 
GEICAM 2006-03 pathological response end-point 
The 5-point scale Miller and Payne histological grading system
18 
was used to 
measure tumor response. In this study, the Miller and Payne scale was reduced to a 3-point 
scale in order to have a fair number of cases in each category and arm: no response (grade 1 
and 2), intermediate response (Grade 3) and high response (Grade 4 and 5). 
 
GEICAM 2006-03 gene expression analysis 
Sixty-three of 95 pre-treatment tumor samples were available for gene expression 
analyses. Total RNA was purified to measure the expression of 543 breast cancer-related 
genes, 5 house-keeping genes and 14 negative and positive controls using the nCounter 
platform (Nanostring Technologies, Seattle, WA, US)
19
. Raw gene expression can be found 
in Supplemental Material. 
 
Independent/testing datasets 
Gene expression and response data were evaluated from 4 independent neoadjuvant 
datasets (Supplemental Material)
14,20-2324
. Gene expression and survival data were 
evaluated from 4 independent datasets of patients with early breast cancer (Supplemental 
Material)2,20,25,26. 
 
Intrinsic subtype assignment 
All tumors were assigned to an intrinsic molecular subtype of breast cancer 
(Luminal A, Luminal B, HER2-enriched, Basal-like) and the normal-like group using the 
research-based PAM50 subtype predictor
27,28
, except for the Malaga cohort where the 
PAM50 standardized and commercial nCounter-based assay was used. Before subtyping, 
each individual dataset was normalized accordingly as previously reported
29
, except for the 
Malaga cohort that was normalized by Nanostring according to their algorithm. Of note, the 
Edinburgh microarray-based dataset is composed of ER+ samples-only and proper 
7  
centering for intrinsic subtyping calling was not possible
30
. In this dataset, CES vas 
evaluated as a continuous variable since it is not affected by centering. 
 
Combined cohort of primary breast cancer 
To evaluate the relationship between PAM50 subtype calls, prognosis (ROR-P) and 
CES, we combined PAM50 data from 7 independent and previously reported 
cohorts
1,2,11,20,31-33 
representing a total of 6,007 primary tumor samples. CES was evaluated 
in each individual cohort, and a combined matrix was created (Supplemental Material). 
 
Statistical analysis 
Biologic analysis of gene lists was performed with DAVID 6.7 annotation tool
34 
using the 543-gene list as background. Association between the expression of each gene 
and Miller-Payne response (3 categories) was assessed by a quantitative Significance 
Analysis of Microarrays (SAM)
35
. In both testing datasets, association between each 
variable and pCR or clinical/radiological response was assessed by univariate and 
multivariable logistic regression analyses. The predictive performance of CES was 
evaluated using receiver operating characteristic (ROC) curve analysis. Estimates of 
survival were from the Kaplan-Meier curves and tests of differences by the log-rank test. 
Univariate and multivariable Cox-models were used to test the independent prognostic 
significance of each variable. Reported P values are two-sided. 
 
 
Results 
GEICAM 2006-03 dataset 
Sixty-three pre- and post-menopausal patients were evaluated in this study (Table 
1). Most patients presented ductal carcinomas (83%), tumor sizes of 2-5 cm (76%), 
histological grade 3 tumors (59%), clinical node-negative disease (54%) and luminal 
disease by PAM50 (84%). 
Following chemotherapy, Luminal B tumors showed higher Miller-Payne response 
than Luminal A disease (mean 2.0 vs. 1.4, P=0.048). However, no difference in response 
between the two luminal subtypes was observed following endocrine therapy (P=0.407). In 
addition, no statistical significant interaction (P=0.429) between subtype and treatment 
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(endocrine vs. chemotherapy) for tumor response was observed. Interestingly, the only 
patient that achieved a pCR (i.e. Miller-Payne Grade 5) had a Basal-like tumor and was 
contained within the chemotherapy arm. 
 
Gene expression association with treatment sensitivity 
To understand the biology associated with either chemotherapy or endocrine 
sensitivity within HR+/HER2- disease, we explored the association between the expression 
of 543 breast cancer-related genes and Miller-Payne response in each treatment arm. High 
expression of 70 (12.9%) and 17 (3.1%) genes was found significantly associated (P<0.05 
uncorrected for multiple comparisons) with response after endocrine therapy and 
chemotherapy, respectively. The gene list associated with endocrine therapy response was 
enriched for the following biological processes (Supplemental Material): vasculature 
development (e.g. AKT1 and catenin beta 1), tube development (e.g. FOXA1 and gremlin 
1) and cell growth (e.g. androgen receptor and fibroblast growth factor receptor 1). On the 
other hand, the gene list associated with chemotherapy response was enriched for cell cycle 
(e.g. EXO1 and MKI67) and extracellular matrix (e.g. netrin 4 and thrombospondin 1). 
We then evaluated the interaction between the expressions of each individual gene 
with response to therapy (endocrine vs. chemotherapy). Interestingly, 41 of the 70 genes 
associated with response to endocrine therapy, and 8 of 17 genes associated with 
chemotherapy response, showed a significant interaction with treatment (P<0.05 
uncorrected for multiple comparisons). Thus, the biological factors associated with 
endocrine sensitivity seemed to be associated, at the same time, with chemotherapy 
resistance, and vice versa. Indeed, an overall inverse pattern was observed between 
expression of most genes and response to treatment (Fig. 1A). 
To further understand the biological factors associated with treatment response, we 
evaluated the mean expression of genes associated with high endocrine but low 
chemotherapy sensitivity, or low endocrine but high chemotherapy sensitivity, across 1,034 
primary tumors representing all intrinsic molecular subtypes of breast cancer (Fig. 1B). The 
results revealed that the biology associated with chemo-endocrine sensitivity is mostly 
driven by the Luminal A (i.e. high endocrine but low chemotherapy sensitive) vs. Basal- 
like biology (i.e. low endocrine but high chemotherapy sensitive). 
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Development of a PAM50-based CES 
Our previous results suggested that capturing the relative differences in the Luminal 
A vs. Basal-like biology within HR+/HER2- could help better predict endocrine and 
chemotherapy sensitivity. To capture this biological state in each tumor, we obtained, from 
the PAM50 classification algorithm, the correlation coefficients (CC) of each sample to the 
PAM50 Luminal A and Basal-like subtype centroids, and then subtracted the 2 values to 
create the Chemo-Endocrine Score (CES=CC to Luminal A – CC to Basal-like). Thus, 
samples with a positive score were identified as being more endocrine sensitive than 
chemotherapy sensitive, whereas samples with a negative score were identified as being 
more chemotherapy sensitive (CES-C) than endocrine sensitive (CES-E) (Fig. 1C). From 
GEICAM 2006-03 samples, cutoffs based on tertiles groups were determined (CES-E vs. 
CES uncertain [CES-U] group, cutoff = 0.70; CES-U vs. CES-C group, cutoff=0.30). The 
interaction of the CES score (as a continuous variable) with treatment in GEICAM 2006-03 
trial provides some evidence of association (P=0.059). 
 
MDACC-based dataset 
We evaluated a combined dataset of 272 patients with HR+/HER2- disease treated 
with anthracycline/taxane-based neoadjuvant chemotherapy across several neoadjuvant 
trials (Table 2). In this dataset, 51.5%, 25.8% and 22.7% of the samples were identified as 
CES-E, -U and -C, respectively. The rates of pCR across the CES-E, -U and -C groups 
were 2.4%, 9.0% and 23.7%, respectively (P<0.0001), and were found to be similar even if 
non-luminal tumors were removed (2.2%, 8.8% and 25.0%). The neoadjuvant 
chemotherapy predictive ability of CES was independent of clinical-pathological variables 
and intrinsic subtype (Table 3 and Table S1). Similar results were obtained when residual 
cancer burden was used as the endpoint (Tables S2-3). 
Six gene expression-based signatures (i.e. PAM50 proliferation score, ROR-P, 
genomic grade index, SET index, chemopredictor, DLDA30 and residual cancer burden 
[RCB] predictor) have been previously reported in this dataset
20
. In addition, we applied a 
microarray-based version of OncotypeDX Recurrence Score
36,37
. Here, we evaluated the 
performance of CES to predict pCR within HR+/HER2- disease compared with these 7 
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gene signatures. Interestingly, CES provided the highest aROC (Table S4-12) either as a 
continuous variable (aROC=0.770) or as group categories (aROC=0.765). The second most 
predictive signature was the RCB predictor (aROC=0.740). Of note, RCB predictor was 
trained using 165 of 272 (60.7%) HR+/HER2- samples from this data set (i.e. the training 
dataset). When these training samples were removed, CES showed a higher performance 
either as a continuous variable (aROC=0.805) or as group categories (aROC=0.786) than 
RCB predictor (aROC=0.640). 
 
Malaga-based dataset 
We evaluated a dataset of 180 patients with HR+/HER2- disease treated with 
anthracycline/taxane-based neoadjuvant chemotherapy (Table 2). In this dataset, 46.1%, 
16.1% and 37.8% of the samples were identified as CES-E, -U and -C, respectively. The 
pCR and RCB 0/1 rates across the CES-E, -U and -C groups were 2.4%/9.6%, 3.4%/17.2% 
and 13.2%/30.9%, respectively (P=0.022 and 0.004). 
To test the ability of CES to predict chemotherapy response independently of 
known clinical-pathological variables and intrinsic subtype, we performed a multivariable 
logistic regression analysis using RCB (0/1 vs. 2/3) as the endpoint since only 12 samples 
achieved a RCB 0 (i.e. pCR) in this dataset. The results revealed that CES provided 
independent predictive information beyond intrinsic subtype (Table 4), Ki-67 by IHC 
(Table S13) and PAM50 ROR score (Table S14). The aROC of CES for predicting RCB 
0/1 was 0.746. Finally, we observed a significant association between CES and Miller- 
Payne response data (Fig. S1). 
 
Marsden-based dataset: CES and endocrine sensitivity 
We evaluated a dataset of 103 post-menopausal patients with HR+ disease treated 
with anastrozole for 16 weeks in the neoadjuvant setting (Table 2). In this dataset, 23.5%, 
34.3% and 42.2% of samples were identified as CES-E, -U and -C, respectively. Clinical 
tumor response (complete and partial response versus stable and progressive disease) was 
used as the endpoint. No pCR was observed in this dataset. The rates of clinical tumor 
response across the CES-E, -U and -C groups were 75.0%, 48.6% and 44.2%, respectively 
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(P=0.043). CES was found to be the only variable significantly associated with response 
(Table S15), independently of HER2 status (Tables S15-16). 
 
Edinburgh-based dataset: CES and endocrine sensitivity 
We evaluated a dataset of 120 post-menopausal patients with HR+ disease treated 
with letrozole for at least 12 weeks in the neoadjuvant setting (Fig. S2A). Two patients of 
120 achieved a complete response. Similar to previous results, CES as a continuous 
variable was found to be the only variable significantly associated with a ≥70% reduction in 
tumor volume by 90 days (Fig. S2B), even within HER2-negative disease (Fig. S2C). 
 
Prognosis, intrinsic subtype and chemo-endocrine sensitivity 
To better understand the relationship between prognosis, intrinsic biology and 
chemo-endocrine sensitivity, we pulled together PAM50 data from many different datasets 
for a total of 6,007 primary breast cancers representing all subtypes (Fig. 2). The results 
revealed that in the ROR-low group, 94.9% of cases were identified as CES-E and 100% 
were of the Luminal A subtype. In the ROR-high, 92.1% of the samples were identified as 
CES-C; non-luminal and Luminal B subtypes represented 64.3% and 35.7% of the ROR- 
high/CES-C cases, respectively. 
In the ROR-intermediate group, high heterogeneity was observed. In terms of 
intrinsic biology, Luminal A, Luminal B and non-Luminal subtypes represented 44.4%, 
31.5% and 24.1%, respectively. In terms of chemo/endocrine-sensitivity, CES-E, CES-U 
and CES-C represented 40.6%, 30.3% and 29.1%, respectively. As expected, the vast 
majority of ROR-intermediate/CES-E samples (77.3%) were of the Luminal A subtype. 
 
Survival outcome of CES within HR+/ROR-intermediate disease 
To continue exploring the value of CES within HR+/ROR-intermediate disease, we 
evaluated the association of CES with survival outcome in HR+/ROR-intermediate early 
breast cancer in 4 independent datasets of patients treated with no adjuvant systemic 
therapy (n=189), adjuvant tamoxifen-only (n=846) or adjuvant chemotherapy and 
endocrine therapy (n=322 and n=148). 
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In patients with node-negative disease treated without adjuvant systemic therapy, 
CES (as a continuous variable or as group categories) was found significantly associated 
with distant relapse-free survival (Fig. 3A). The hazard ratio between the CES-C group vs 
the CES-E group was 2.68 (0.163–0.858 95% confidence interval). Similar results were 
obtained in the dataset where patients were treated with adjuvant tamoxifen-only (Fig. 3B). 
However, CES (as a continuous variable or as group categories) was not found significantly 
associated with survival outcome in 2 independent cohorts of patients treated with 
(neo)adjuvant chemotherapy and endocrine therapy (Fig. 3C and D). 
 
Discussion 
Our results are the first to confirm, in a randomized setting, an inverse relationship 
of endocrine and chemotherapy sensitivity in ER+ breast cancer. Previous evidence has 
suggested an inverse relationship of proliferation- and ER-related biological processes 
regarding endocrine and chemotherapy sensitivity of ER+ breast cancer. For example, two 
independent studies showed an inverse correlation between a 200-gene ER reporter score, 
or between TAU expression, an ER-related gene, and endocrine sensitivity and 
chemosensitivity
38,39
. In addition, high recurrence score measured by Oncotype DX 
(Genomic Health, Inc., Redwood, CA) predicted little or no benefit from adjuvant 
tamoxifen therapy in the NSABP-B14 trial, but at the same time also predicted substantial 
benefit from adjuvant CMF chemotherapy in the NSABP-B20 trial
40,41
. These results fit 
with our results showing that virtually all patients with ROR-high disease are identified as 
CES-C; however, our data also highlights that within ROR-high/CES-C disease not all 
ER+/HER2- samples are luminal (i.e. Luminal A or B) since non-luminal disease (i.e. 
Basal-like and HER2-enriched) can also be identified. According to our results (Fig. 2), the 
chemotherapy benefit of ROR-high/non-luminal tumors within HR+/HER2- disease is 
likely even greater than ROR-high/Luminal B tumors. 
Our results also suggest that a main driver of endocrine therapy sensitivity and 
chemotherapy sensitivity within ER+/HER2- disease is the Basal-like versus Luminal A 
intrinsic biology. To capture both biological states in each individual sample, we calculated 
the correlation coefficients of each sample to both PAM50-centroids (i.e. Luminal A and 
Basal-like) and then subtracted both coefficients. Thus, instead of choosing a gene 
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signature (e.g. a proliferation-based signature) of the many signatures that can discriminate 
between both subtypes in one way or another, we decided to incorporate into a score the 
Basal-like vs. Luminal A intrinsic state of each tumor as identified by the PAM50 subtype 
predictor. Of note, the PAM50 genes were originally selected for their ability to capture the 
intrinsic biology displayed by 1,900 genes (i.e. the so-called intrinsic gene list). In fact, in 
the TCGA, intrinsic subtype defined by PAM50 captured the vast majority of the biological 
diversity displayed by most molecular data-types analyzed
1
. 
From a clinical perspective, our results support current breast cancer guidelines for 
the systemic treatment of early HR+/HER2- breast cancer. On one hand, patients with a 
low-ROR score and a low tumor burden (i.e. <10% risk of distant relapse at 10 years) are 
recommended to be treated with endocrine therapy-only
42
. Indeed, our results suggest that 
these patients have tumors that are highly endocrine sensitive and have low chemotherapy 
sensitivity. On the other hand, patients with high-risk HR+/HER2- disease are 
recommended to be treated with endocrine therapy and chemotherapy. According to our 
analysis, this group is the one with high chemotherapy benefit and low endocrine benefit. 
Regarding endocrine therapy in this group, the main issue is that we do not have survival 
data suggesting that CES-C tumors do not benefit at all from endocrine therapy. Therefore, 
withdrawal of a potentially efficacious treatment strategy such as endocrine therapy in a 
patient with an ER+ tumor (as defined by the ASCO/CAP guidelines) that is identified as 
CES-C or ROR-high should not be recommended today, although in patients whose tumors 
contain low levels of ER (1% to 10%), ASCO/CAP recommend to discuss the pros and 
cons of endocrine therapy. A large randomized adjuvant trial involving thousands of 
patients to answer this particular question is unlikely to happen. 
Although the clinical implications of CES in low and high risk HR+/HER2- disease 
are minimal, the observation that intermediate risk HR+/HER2- disease, which represents 
30% of newly diagnosed breast cancer, is biologically heterogeneous with a range of 
chemotherapy sensitivities might have implications for the interpretation of two ongoing 
prospective clinical trials. In the TailorX phase III trial, 4,500 patients with HR+/HER2- 
node-negative early breast cancer with intermediate RS have been randomized to adjuvant 
chemotherapy or no chemotherapy. According to our analysis, this intermediate group 
might be composed of at least 3 groups with different chemotherapy sensitivities. Of note, 
14  
the CES-U group seems to be a genuine grey area where decisions regarding the need of 
chemotherapy might be difficult. A similar situation might occur in the RxPONDER phase 
III clinical trial where patients with HR+/HER2- early breast cancer, and 1-3-positive 
lymph nodes, with low/intermediate risk are being randomized to adjuvant chemotherapy or 
not. A potential explanation is that OncotypeDX RS, as well as other prognostic gene 
expression-based tests, such as PAM50 ROR or MammaPrint
43
, have been specifically 
designed or trained to predict outcome and not intrinsic tumor biology or treatment 
sensitivity. Although a strong negative correlation is observed between ROR (risk) and 
CES (drug sensitivity), there are substantial differences between them at the individual 
level (40% discordance). 
There are several caveats to our study. First, this is a retrospective study involving 
heterogeneous patient populations and the results need to be confirmed in a prospective 
clinical trial(s). Second, although the data presented here validates CES from a clinical 
perspective, further analytical validation will be needed since in most datasets, except the 
Malaga set, the research-based version of PAM50 was used. However, the fact that CES (as 
a continuous variable and the 2 cut-points) predicted pCR in the Malaga set suggests that 
analytical validation of this biomarker is feasible. Third, we did not evaluate the association 
of CES with survival data from a randomized clinical trial of adjuvant chemotherapy vs no 
adjuvant chemotherapy, or adjuvant endocrine therapy versus no adjuvant endocrine 
therapy. Thus, the predictive value of these signatures was only evaluated in the 
neoadjuvant setting where different tumor response endpoints were evaluated, most of 
which have been associated with patient survival
18,44
. Fourth, some of the signatures 
evaluated in the MDACC-based dataset, such as OncotypeDX recurrence score or genomic 
grade index, were derived from microarray-based data and thus are not the commercially 
available versions. Fifth, we were not able to demonstrate a consistent association of CES 
with endocrine response in HR+ disease after excluding the HER2-positive cases. In the 
Edinburgh dataset, HER2 status was not available for all patients. Although we derived an 
ERBB2 expression-based surrogate definition of HER2 status and showed that CES is 
independently associated with response, this was not prespecified and does not meet 
REMARK guidelines. In addition, the association of CES with endocrine response did not 
reach statistical significance (p=0.09) in patients with HR+/HER2-negative disease in the 
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Marsden dataset. Finally, patients from each of the datasets received different 
anthracycline/taxane-based chemotherapy regimens, schedules and doses, and thus the 
ability of the signatures to predict response to particular chemotherapeutics or treatment 
regimens could not be tested. 
Another important consideration of our study is that we did not attempt to identify 
an optimal cutoff(s) for CES but rather focused on the association of the continuous 
expression of CES with each endpoint. The main reason is that different gene expression- 
based platforms and protocols were used in each cohort and thus, standardization of a 
biomarker cut-point would have been difficult to achieve and most likely unreliable. In any 
case, the fact that all four testing sets gave very similar associations, and were found 
independently of the platform/protocol used, argues in favor of a robust finding. 
To conclude, CES is a single genomic signature capable of measuring chemo- 
endocrine sensitivity in HR+/HER2- breast cancer beyond intrinsic subtype, other genomic 
signatures, and the standard pathology variables. CES could be of particular clinical value 
in patients with HR+/HER2- intermediate risk disease where the benefit of adjuvant multi- 
agent chemotherapy is unclear. 
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Tables 
 
Table 1. Clinical-pathological characteristics and subtype distribution in the GEICAM 
2006-03 study*. 
 
 
   
 
 
 
 
 
1.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*CT, chemotherapy arm; ET, endocrine therapy arm. 
 CT %  ET %  P-value 
Num. 32 -  31 -  - 
Age (mean) 53.7 -  52.3 -  0.596 
Menopausal status        
Pre-menopausal 14 44%  14 45% 
Post-menopausal 18 56%  17 55% 
Tumor stage 
T1 
 
1 
 
3% 
  
2 
 
6% 
  
T2 23 72%  25 81%  0.420 
T3 8 25%  4 13%   
Mean tumor size (cm) 4.2   3.8   0.278 
Node 
N0 
 
15 
 
47% 
  
19 
 
61% 
  
N1 16 50%  11 35%  0.501 
N2 1 3%  1 3%   
Grade 
G1 
 
0 
 
0% 
  
0 
 
0% 
  
G2 8 25%  6 19%   
G3 18 56%  19 61%  0.862 
G4 6 19%  6 19%   
Histological Type 
Ductal 
 
26 
 
81% 
  
26 
 
84% 
  
Lobular 2 6%  2 6%  1.000 
Others 4 13%  3 10%   
Ki-67 IHC (mean) 31.1   33.5   0.720 
Miller-Payne Response (mean) 2.6   2.2   0.124 
PAM50 
Luminal A 
 
16 
 
50% 
  
13 
 
42% 
  
Luminal B 11 34%  13 42%   
HER2-E 0 0%  1 3%  0.564 
Basal-like 2 6%  0 0%   
Normal-like 3 9%  4 13%   
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Table 2. Clinical-pathological characteristics and subtype distribution of the 4 testing sets*. 
MDACC Malaga Marsden Edinburgh 
 
 N %  N %  N %  N % 
Treatment CT   CT   ET   ET  
N 272   180   103   120  
HER2 status
¥
 
HER2-negative 
 
272 
 
100% 
  
180 
 
100% 
  
89 
 
86% 
  
31 
 
69% 
HER2-positive 0 0%  0 0%  14 14%  14 31% 
Age (mean) 50.1   50.0   53.7   76.1  
Menopausal status 
Pre-menopausal 
 
NA 
   
108 
 
60% 
  
0 
 
0% 
  
0 
 
0% 
Post-menopausal NA   72 40%  103 100%  120 100% 
Tumor stage 
 
60 58% 
 
43 42% 
 
Node      
61 
 
59% 
 
86 
 
72% N0 96 35% 67 37% 
N1 
N2-N3 
133 
43 
49% 
16% 
61 
52 
34% 
29% 
39 
3 
38% 
3% 
34 28% 
Grade 
 
G1 28 11% 27 16% 15 15% 13 11% 
G2 136 53% 96 57% 63 62% 82 68% 
G3 91 36% 46 27% 24 23% 25 21% 
ET response rate
§
 NA  NA  53%  72%  
CT response rate 
pCR breast/axilla 
 
8.8% 
  
6.7% 
  
NA 
  
NA 
 
T0-T1 19 7% 18 10% 
T2 142 52% 115 67% 
T3-T4 111 41% 39 23% 
 
10 9% 
42 36% 
63 55% 
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*, ET, endocrine therapy; CT, chemotherapy. ¥, Edinburgh dataset has 75 patients without clinical HER2 status. § The definition of ET 
response is different in the Marsden and Edinburgh datasets. Clinical tumor response (complete and partial response versus stable and 
progressive disease) was used as the endpoint in the Marsden dataset. Response was evaluated by imaging ultrasound in the Edinburgh 
dataset. Clinical tumor response was defined as tumor volume shrinkage of at least 70% by 90 days of treatment. 
PAM50 
Luminal A 
Luminal B 
HER2-E 
Basal-like 
Normal-like 
141 
102 
6 
7 
16 
52% 
38% 
2% 
2% 
6% 
54 
105 
7 
14 
- 
30% 
58% 
4% 
8% 
- 
37 
20 
12 
4 
30 
36% 
19% 
12% 
4% 
29% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
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Table 3. CES association with chemotherapy sensitivity in the MDACC-based dataset. 
 
Univariate Analysis Multivariable Analysis 
 
  
 
Signatures N 
pCR 
rate 
OR 
Lower 
95% 
Upper 
95% 
p- 
value 
OR
 
Lower 
95% 
Upper 
95% 
p- 
value 
 
Tumor size 
T0-T2 
 
153 
 
8% 
 
1.0 
 
- 
 
- 
 
- 
 
1.0 
 
- 
 
- 
 
- 
T3-T4 107 9% 1.1 0.47 2.63 0.813 0.6 0.22 1.70 0.341 
Nodal status 
N0 
 
96 
 
7% 
 
1.0 
 
- 
 
- 
 
- 
 
1.0 
 
- 
 
- 
 
- 
N1 125 9% 1.2 0.46 3.29 0.685 0.9 0.30 2.78 0.882 
N2-3 39 13% 1.9 0.56 6.29 0.312 1.0 0.24 4.51 0.965 
Grade 
1 
 
26 
 
4% 
 
1.0 
 
- 
 
- 
 
- 
 
1.0 
 
- 
 
- 
 
- 
2 130 4% 1.0 0.11 8.93 1.000 0.7 0.07 6.88 0.753 
3 89 17% 5.1 0.64 40.34 0.125 1.8 0.18 18.42 0.608 
PAM50           
Luminal A 134 3% 1.0 - - - 1.0 - - - 
Luminal B 99 15% 5.8 1.86 18.08 0.002 1.2 0.25 6.28 0.792 
HER2-E 6 0% 0.0 - - 0.989 0.0 - - 0.991 
Basal-like 7 29% 13.0 1.91 88.50 0.009 0.4 0.02 9.97 0.586 
Normal-like 14 14% 5.4 0.90 32.69 0.065 1.7 0.23 12.75 0.602 
CES           
CES-E 134 2% 1.0 - - - - - - - 
CES-U 67 9% 4.3 1.04 17.75 0.044 - - - - 
CES-C 59 24% 13.6 3.73 49.46 <0.001 - - - - 
CES (cont. variable) - - 0.2 0.08 0.40 <0.001 0.2 0.03 0.77 0.022 
Age (cont. variable) - - 1.0 0.93 1.02 0.251 1.0 0.92 1.02 0.205 
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Table 4. CES association with chemotherapy sensitivity in the Malaga dataset. 
 
 
Univariate Analysis Multivariable Analysis 
 
 
Signatures 
 
N 
 
RCB0/1 
rate 
 
OR 
 
Lower 
95% 
 
Upper 
95% 
 
p- 
value 
  
OR 
 
Lower 
95% 
 
Upper 
95% 
 
p-value 
Age (cont. variable) - - 1.0 0.95 1.02 0.331  1.0 0.96 1.07 0.599 
Tumor size 
T0-T2 
 
133 
 
22% 
 
1.0 
 
- 
 
- 
 
- 
  
1.0 
 
- 
 
- 
 
- 
T3-T4 39 10% 0.4 0.13 1.25 0.116  0.4 0.09 1.90 0.260 
Grade 
1 
 
27 
 
7% 
 
1.0 
 
- 
 
- 
 
- 
  
1.0 
 
- 
 
- 
 
- 
2 96 16% 2.3 0.50 10.82 0.286  1.6 0.26 9.31 0.625 
3 46 35% 6.7 1.40 31.82 0.017  3.0 0.40 23.34 0.283 
PAM50            
Luminal A 54 9% 1.0 - - -  1.0 - - - 
Luminal B 105 20% 2.4 0.87 6.91 0.090  0.9 0.19 4.34 0.905 
HER2-E 7 14% 1.6 0.16 16.43 0.677  0.1 0.00 3.19 0.188 
Basal-like 14 50% 9.8 2.43 39.51 0.001  0.1 0.00 3.40 0.214 
CES            
CES-E 83 10% 1.0 - - -  - - - - 
CES-U 29 17% 2.0 0.58 6.54 0.277  - - - - 
CES-C 68 31% 4.2 1.72 10.22 0.002  - - - - 
CES (cont. variable) - - 0.2 0.09 0.44 <0.001  0.2 0.07 0.76 0.016 
 Figure Legends 
 
 
Fig 1. Gene expression association with either chemotherapy or endocrine therapy 
sensitivity. (A) Association between the expression of each individual gene (n=542) and 
Miller-Payne response in each arm of the GEICAM 2006-03 trial. Selected top genes who´s 
expression is found significantly associated with response are shown on the right. (B) Mean 
expression of the Top 50 genes associated with endocrine sensitivity (upper panel) and 
chemotherapy sensitivity (bottom panel) in the GEICAM 2006-03 trial across the intrinsic 
subtypes of breast cancer. The RNAseq-based gene expression data has been obtained from 
the The Cancer Genome Atlas breast cancer project data portal (https://tcga- 
data.nci.nih.gov/tcga/). (C) Significance and scoring of the CES. 
 
  
 Fig 2. Prognosis (PAM50 ROR), intrinsic subtype and CES in 6,007 primary breast 
cancers. (A) A scatter plot of CES score and ROR score, colored by subtype, is shown. The 
two horizontal lines indicate the cutoffs of each CES group. The two vertical lines indicate 
the cutoffs of each PAM50 ROR group. (B) Number of patients in each CES group based 
on ROR. Each bar is colored by subtype. 
 
 
 
  
 Fig 3. Survival outcomes in HR+ early breast cancer with ROR-intermediate disease. (A) 
Node-negative disease treated without adjuvant systemic therapy. (B) Node-negative and 
node-positive disease treated with adjuvant tamoxifen-only. (C) Node-positive disease 
treated with adjuvant chemotherapy and endocrine therapy in the GEICAM/9906 clinical 
trial. (D) Node-negative and node-positive disease treated with neoadjuvant chemotherapy 
and adjuvant endocrine therapy. 
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